Bisphosphonates induced osteonecrosis of the jaw의 기전, 예방, 위험 평가 및 치료 방법 = Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw

다국어 초록 (Multilingual Abstract)

Purpose: Bisphosphonates are drugs used to suppress osteoclastic activity and to treat osteoporosis, Paget's disease of bone and bone metastasis. The purpose of this report is to review the literatures on bisphosphonates use that could affect bone healing and cause osteonecrosis of the jaws. Materials and methods: Medline research was carried out to find relevant articles on bisphosphonates and osteonecrosis of the jaw. Results: Oral administration of bisphosphonates is reported to decrease the risk of adverse bone outcomes. On the contrary, IV bisphosphonates is known to significantly increase the risk. Prevention of the osteonecrosis of the jaw is primary concern before usage. If the adverse bone reaction takes place, proper management and treatments are required to alleviate pain of patients and prevent further progression of necrosis. Conclusion: Case reports of bisphosphonates induced osteonecrosis of the jaw are increasing. Dentists and physicians should be aware of the higher frequency of osteonecrosis of the jaw in patients receiving IV bisphosphonates and be prepared to prevent and cope with adverse bone reaction.

참고문헌 (Reference)

1 Reid IR, "bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity?" 41 : 318-320, 2007

2 Etminan M, "Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study" 35 : 691-695, 2008

3 Edwards BJ, "Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on ScientificAffairs" 139 : 1674-1677, 2008

4 Epstein S, "Update of current therapeutic options for the treatment of postmenopausal osteoporosis" 28 : 151-173, 2006

5 Rosen HN, "Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy" 66 : 100-103, 2000

6 Jeffcoat MK, "Safety of oral bisphosphonates: controlled studies on alveolar bone" 21 : 349-353, 2006

7 Walter C, "Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis" 15 : 197-202, 2007

8 Marx RE, "Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic" 61 : 1115-1117, 2003

9 Ficarra G, "Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment" 32 : 1123-1128, 2005

10 Brooks JK, "Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases" 103 : 780-786, 2007

11 Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases" 62 : 527-534, 2004

12 Bilezikian JP, "Osteonecrosis of the jaw--do bisphosphonates pose a risk?" 355 : 2278-2281, 2006

13 Badros A, "Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors" 24 : 945-952, 2006

14 Bamias A, "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors" 23 : 8580-8587, 2005

15 Rinchuse DJ, "Orthodontic treatment of patients using bisphosphonates: a report of 2 cases" 131 : 321-326, 2007

16 Wynn RL, "Oral bisphosphonates and osteonecrosis of the jaw" 55 : 8-10, 2007

17 Marx RE, "Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment" 65 : 2397-2410, 2007

18 Sedghizadeh PP, "Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry" 140 : 61-66, 2009

19 Black DM, "Once-yearly zole dronic acid for treatment of postmenopausal osteoporosis" 356 : 1809-1822, 2007

20 Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia" 65 : 415-423, 2007

21 Woo SB, "Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws" 144 : 753-761, 2006

22 Bagan JV, "Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases" 42 : 327-329, 2006

23 Hansen T, "James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis" 35 : 155-160, 2006

24 Grbic JT, "Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial" 139 : 32-40, 2008

25 Brunski JB, "In vivo bone response to biomechanical loading at the bone/dental-implant interface" 13 : 99-119, 1999

26 IMS, "HEALTH" NPA Plus 2006

27 Lehenkari PP, "Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite" 61 : 1255-1262, 2002

28 Benford HL, "Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs" 56 : 131-140, 1999

29 Fleisch H, "Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis" 212 : 901-903, 1966

30 Wang HL, "Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report" 78 : 584-594, 2007

31 Vignery A, "Dynamic histomorphometry of alveolar bone remodeling in the adult rat" 196 : 191-200, 1980

32 Fleisch H, "Development of bisphosphonates" 4 : 30-34, 2002

33 Rogers MJ, "Cellular and molecular mechanisms of action of bisphosphonates" 88 : 2961-2978, 2000

34 Friberg B, "Branemark implants and osteoporosis: a clinical exploratory study" 3 : 50-56, 2001

35 Dixon R, "Bone turnover in elderly canine mandibles and tibia" 76 : 2579-, 1997

36 Green JR, "Bisphosphonates: preclinical review" 9 (9): 3-13, 2004

37 Fournier P, "Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats" 62 : 6538-6544, 2002

38 Sawatari Y, "Bisphosphonates and bisphosphonate induced osteonecrosis" 19 : 487-498, 2007

39 McClung MR, "Bisphosphonates" 32 : 253-271, 2003

40 Boonyapakorn T, "Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies" 44 : 857-869, 2008

41 Marx RE, "Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment" 63 : 1567-1575, 2005

42 Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research" 22 : 1479-1491, 2007

43 Cartsos VM, "Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people" 139 : 23-30, 2008

44 Migliorati CA, "Bisphosphanates and oral cavity avascular bone necrosis" 21 : 4253-4254, 2003

45 Schwartz JE, "Ask us: Some drugs affect tooth movement" 127 : 644-, 2005

46 Owens G, "An integrated approach: bisphosphonate management for the treatment of osteoporosis" 13 (13): S290-S308, 2007

47 Berenson JR, "American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma" 20 : 3719-3736, 2002

48 "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws" 65 : 369-376, 2007

49 Bergstrom JD, "Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase" 373 : 231-241, 2000

50 Alakangas A, "Alendronate disturbs vesicular trafficking in osteoclasts" 70 : 40-47, 2002